Wuxi Bio (02269) repurchased 3.0365 million shares on June 5 at a cost of HK$99.8191 million.

Wuxi Bio (02269) announced that on June 5, 2026, the company repurchased 3.0365 million shares at a cost of HK$99.8191 million.

Zhitong FinanceJun 5 20:35

WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility

PR NewswireJun 5 10:45

ASCO data and multi-billion-dollar business development deals resonated positively, driving the Hang Seng Healthcare ETF (ChinaAMC) (520510) up 1.3%, with the Hang Seng Healthcare ETF (ChinaAMC) (159892) also rising in tandem.

Gelonghui, June 5 | The innovative pharmaceuticals sector was active today, with Kelun Biotech and Asymchem rising by 6%, driving a 1.3% increase in the Hang Seng Healthcare ETF (ChinaAMC) (520510) and a 0.7% gain in the Hang Seng Healthcare ETF (ChinaAMC) (159892). The sector’s recent strength stems from a combination of impressive clinical data, landmark overseas licensing deals, and supportive government policies. ① Outstanding data presented at ASCO Annual Meeting: At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chinese innovative drug developers such as Akeso, Kelun Biotech, and Betta Pharmaceuticals delivered strong performances, with a total of 94 studies selected for oral presentations and 12 studies included

Gelonghui FinanceJun 5 10:13

June 4 Buyback Roundup | AIA, Tencent, and others announced share repurchases, with AIA spending HK$659 million.

According to a filing disclosed by the Hong Kong Exchange on June 5, AIA (01299.HK), Tencent (00700.HK), and others repurchased shares. ① AIA (01299.HK) repurchased 8.325 million ordinary shares on June 4, for a total consideration of HK$659 million, at prices ranging from HK$81.6 to HK$76.8 per share. Since the adoption of the share repurchase mandate, the cumulative number of securities repurchased amounts to 54.0656 million shares, representing 0.5172% of the issued share capital as of the date the ordinary resolution was passed. ② Tencent (00700.HK)

Futu NewsJun 5 09:20

Wuxi Bio (02269) repurchased 1.5265 million shares on June 4 at a cost of HK$49.6522 million.

Wuxi Bio (02269) announced that on June 4, 2026, the company repurchased 1.5265 million shares at a total cost of HK$49.6522 million, with repurchase prices ranging from HK$32.22 to HK$32.94 per share.

Zhitong FinanceJun 4 21:27

Wuxi Bio (2269.HK): Commercialization Pathway Becomes Clearer as Global Landscape Enters a Rebalancing Phase

Based on the industry-leading rapid growth of its bispecific and multispecific antibody programs and the continued realization of late-stage pipeline trends, the company has provided for the first time a medium-term target of approximately 20% compound annual revenue growth (CAGR) over the next three years, further enhancing its medium- to long-term visibility. Framework agreements with major pharmaceutical companies

CITIC SecuritiesJun 4 17:17